Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Foot-and-mouth vaccine breakthrough
Image: Cell infected with FMDV, SourceWire
New vaccine is a leap forward in disease control

New methodology has been developed to produce a synthetic vaccine for foot-and-mouth disease virus (FMDV). The new vaccine does not rely on growing the live infectious virus, and is therefore much safer to produce than traditional vaccines.

The research has been led by Professor David Stuart, life science director at Diamond Light Source, and MRC Professor of structural biology at the University of Oxford, and Dr Bryan Charleston, head of livestock viral diseases programme at the Pirbright Institute.

The new vaccine is made up of tiny protein shells designed to trigger optimum immune response. These have been engineered for increased stability, making the vaccine easier to store and reducing the need for a cold chain. Dr Charleston says this will "greatly increase production capacity and reduce costs," addressing the current problem of undersupply due to costs.

The work could also have implications for the control of other viruses, such as polio. Lead researcher Professor Stuart said: "Unlike the traditional vaccines, there is no chance that the empty shell vaccine could revert to an infectious form.

"This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to viruses from the same family, such as poliovirus and hand foot and mouth disease."

Key results of the research were published in PLOS Pathogens journal last week. Clinical trials on cattle showed the synthetic vaccine is just as effective as current vaccines, and is stable at temperatures of up to 56°C for at least two hours. This has clear advantages in fighting the disease central Africa and some parts of the Middle East and Asia where it is endemic.

Professor Stuart explained that the team are using a methodology developed by Professor Ian Jones of the University of Reading. This involves creating empty protein shells to imitate the protein coat that forms the strong outer layer of the virus.

By combining Diamond's visualisation capabilities with the expertise of Oxford University in structural analysis and computer simulation, the team were able to "visualise something a billion times smaller than a pinhead" and enhance the design of the empty shells "atom by atom". Researchers could also verify that these shells have "essentially the same structure as the native virus".

Commenting on the vaccine, the UK's chief veterinary officer Nigel Gibbens said: "This vaccine is a major breakthrough that has the potential to be an invaluable new weapon in the fight to eradicate foot-and-mouth disease."

Gibbens concluded: "This vaccine has been developed using some truly groundbreaking techniques which are a credit to the quality of British scientists working in the field of animal health."

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.